Streetbeat News

Stock Prices

SEE

Sealed Air Corporation has reduced its FY23 revenue forecast from $5.85B-$6.10B to $5.40B-$5.60B, which is below the estimated $5.86B.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:17 am

EEMA

EWU

EZU

FLAX

SPY

US markets ended higher on Monday, with Dow Jones adding over 400 points. Asian markets saw mixed results, with Japan's Nikkei 225 and Australia's S&P/ASX 200 ending higher, while Shanghai Composite and Hang Seng index fell. European markets and commodities traded lower, while US futures were also down. The U.S. Dollar Index was up.

Portfolio Pulse from Akanksha Bakshi

August 08, 2023 | 11:17 am

PRAX

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced further data from two additional analyses of the Essential1 study for ulixacaltamide. The results showed maintained or improved efficacy in patients dosed up to 14 weeks. Ulixacaltamide is a small molecule inhibitor of T-type calcium channels being developed for Essential Tremor.

Portfolio Pulse from Charles Gross

August 08, 2023 | 11:16 am

TDG

TransDigm Gr (NYSE:TDG) reported Q3 adjusted earnings of $7.25 per share, beating the analyst consensus estimate of $6.33 by 14.53%. This is a 49.48% increase from the same period last year. The company also reported quarterly sales of $1.74 billion, beating the analyst consensus estimate of $1.68 billion by 4.00%, a 24.75% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:16 am

RPRX

Royalty Pharma Plc (NASDAQ:RPRX) has updated its FY23 adjusted cash receipts guidance to $2.90B-$2.975B, up from the previous guidance of $2.850B-$2.950B. This represents an underlying growth of 6% to 10% prior to the Zavzpret milestone payment in Q1 2023 and the payments related to the Biohaven Preferred Shares received in 2022.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:15 am

SEE

Sealed Air (NYSE:SEE) reported Q2 adjusted earnings of $0.80 per share, beating the analyst consensus estimate of $0.68 by 17.65%. However, this is a 20.79% decrease from the same period last year. The company's quarterly sales of $1.38 billion missed the analyst consensus estimate of $1.42 billion by 2.54%, marking a 2.68% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:14 am

NOVT

Novanta has reduced its FY23 adjusted EPS outlook from $3.00-$3.20 to $2.96-$3.15, which is slightly below the estimated $3.14.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:13 am

NOVT

Novanta has revised its FY23 GAAP revenue outlook downwards from $890M-$915M to $892M-$902M, which is below the estimated $907.77M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:12 am

GFS

GlobalFoundries has projected its Q3 revenue to be between $1.825B and $1.870B, which is lower than the estimated $1.88B. The company also expects its adjusted EPS to be between $0.46 and $0.54, compared to the estimated $0.52.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:11 am

CLBT

Cellebrite DI has raised its FY2023 sales guidance from $305.00M-$315.00M to $310.00M-$320.00M, compared to the $310.75M estimate. The company's updated expectations also include an increase in growth over 2022, December 2023 ARR, 2023 Adjusted EBITDA, and 2023 Adjusted EBITDA margin.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:10 am